These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6184410)

  • 1. Regulation of the immune response to tumor antigens. IX. In vitro Lyt-1+2- cell proliferative responses to cellbound or subcellular tumor antigen.
    Carter RH; Drebin JA; Schatten S; Perry LL; Greene MI
    J Immunol; 1983 Feb; 130(2):997-1002. PubMed ID: 6184410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of the immune response to tumor antigens. X. Activation of third-order suppressor T cells that abrogate anti-tumor immune responses.
    Schatten S; Drebin JA; Perry LL; Chung W; Greene MI
    J Immunol; 1984 Aug; 133(2):1064-9. PubMed ID: 6234349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
    Roberts LK
    J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the immune response to tumor antigen. VI. Differential specificities of suppressor T cells or their products and effector T cells.
    Greene MI; Perry LL
    J Immunol; 1978 Dec; 121(6):2363-6. PubMed ID: 82582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential antigen presentation in tumor immunity.
    Schatten S; Drebin JA; Granstein RD; Greene MI
    Fed Proc; 1984 Jun; 43(9):2460-4. PubMed ID: 6327399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enterically induced regulation of systemic immune responses. II. Suppression of proliferating T cells by an Lyt-1+, 2- T effector cell.
    Silverman GA; Peri BA; Fitch FW; Rothberg RM
    J Immunol; 1983 Dec; 131(6):2656-61. PubMed ID: 6196395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell regulation of B cell activation: antigen-specific and antigen-nonspecific suppressor pathways are mediated by distinct T cell subpopulations.
    Asano Y; Hodes RJ
    J Immunol; 1983 Mar; 130(3):1061-5. PubMed ID: 6185568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the immune response to tumor antigen. IV. Tumor antigen-specific suppressor factor(s) bear I-J determinants and induce suppressor T cells in vivo.
    Perry LL; Benacerraf B; Greene MI
    J Immunol; 1978 Dec; 121(6):2144-7. PubMed ID: 82578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rat anti-mouse T4 monoclonal antibody (H129.19) inhibits the proliferation of Ia-reactive T cell clones and delineates two phenotypically distinct (T4+, Lyt-2,3-, and T4-, Lyt-2,3+) subsets among anti-Ia cytolytic T cell clones.
    Pierres A; Naquet P; Van Agthoven A; Bekkhoucha F; Denizot F; Mishal Z; Schmitt-Verhulst AM; Pierres M
    J Immunol; 1984 Jun; 132(6):2775-82. PubMed ID: 6202760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory role of T lymphocytes and NK cells in tumor allograft development.
    Sobotková E; Nouza K
    Neoplasma; 1993; 40(2):75-80. PubMed ID: 8350958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a continuous T cell line capable of suppressing anti-tumor immune responses in vivo.
    Roberts LK; Spellman CW; Warner NL
    J Immunol; 1983 Jul; 131(1):514-9. PubMed ID: 6223081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonspecific inhibitor of DNA synthesis elaborated by T acceptor cells. I. Specific hapten- and I-J-driven liberation of an inhibitor of cell proliferation by Lyt-1-2+ cyclophosphamide-sensitive T acceptor cells armed with a product of Lyt-1+2+-specific suppressor cells.
    Malkovský M; Asherson GL; Chandler P; Colizzi V; Watkins MC; Zembala M
    J Immunol; 1983 Feb; 130(2):785-90. PubMed ID: 6217254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors.
    Schmid DS; Rouse BT
    J Immunol; 1983 Jul; 131(1):479-84. PubMed ID: 6223080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
    Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
    J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
    Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
    Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
    Izumi Y; Tsuchida T; Okuno K; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.